iCAD announced Thursday, July 11, that its ProFound AI solution for 2D mammography has gained CE mark approval. The company’s ProFound AI for Digital Breast Tomosynthesis (DBT) received the mark back in March 2018.
ProFound AI for 2D Mammography, the most recent addition to iCAD’s ProFound AI platform, is an AI algorithm that uses deep learning to analyze a patient’s mammography images and provides radiologists with key information.
“Europe contains 9% of the world’s population but has more than 23% of the global cancer burden, with breast cancer being the most common cancer among European women,” Stacey Stevens, president of iCAD, said in a prepared statement. “This CE mark further validates our ProFound AI platform as a world-class artificial intelligence solution that offers benefits to both radiologists and screening-aged women in detecting breast cancer. iCAD is committed to improving patient care worldwide and we are pleased to offer this powerful technology to a growing number of hospitals, imaging centers and women across Europe.”
“ProFound AI for 2D Mammography has the potential to assist radiologists in their interpretation of 2D mammography images, as we have seen with ProFound AI for DBT,” Axel Gräwingholt, MD, Radiologie am Theater in Paderborn, Germany, said in the same statement.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.